SCHEDULE: Armistice Capital Reports 2.56% Stake in Intensity
Beneficial Ownership Report
Armistice Capital and Steven Boyd report a 2.56% beneficial ownership stake in Intensity Therapeutics, Inc. common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively report beneficial ownership of 1,237,113 shares of Intensity Therapeutics, Inc. common stock.
- This represents 2.56% of the outstanding common stock of Intensity Therapeutics, Inc.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over the reported shares.
- The filing is an Amendment No. 2 to a previously filed Schedule 13G.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and contains no information related to company performance, strategic updates, or future outlook, thus indicating a neutral sentiment.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership report.
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment firm and does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd is the managing member of Armistice Capital, LLC. This structure defines the beneficial ownership relationship.
Stakeholder Impact
- This filing has minimal direct impact on shareholders, employees, customers, suppliers, or creditors as it is a routine disclosure of a passive investment stake below the 5% threshold, not indicating a change in control or activist intent.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement |
| 08/14/2025 | Date of filing of this statement |
Keywords
Intensity Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.